VolitionRx Gains NYSE Acceptance of Plan to Meet $2M–$6M Equity Thresholds by Aug 2027
On April 22, 2026, the NYSE American accepted VolitionRx’s compliance plan to regain Sections 1003(a)(i)-(iii) equity thresholds of $2.0 million, $4.0 million and $6.0 million, granting until August 6, 2027 to meet listing standards. The company submitted the plan before the March 8 deadline, preserving its NYSE American listing and trading during periodic reviews.
1. Compliance Plan Accepted
On April 22, 2026, the NYSE American accepted VolitionRx’s compliance plan, allowing its common stock to remain listed and traded during the plan period without immediate delisting action.
2. Listing Standards Non-Compliance
VolitionRx received a notice on February 6 for failing to meet Sections 1003(a)(i)-(iii) of the NYSE American Company Guide, which require minimum stockholders’ equity of $2.0 million, $4.0 million and $6.0 million based on recent net loss history.
3. Compliance Period and Risks
The company has until August 6, 2027 to regain compliance and will face periodic reviews of its progress; failure to satisfy listing standards or demonstrate sufficient progress could prompt delisting proceedings.